Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (pilot cohort study with short walking objectives) - PERIPATEI
A legfontosabb adatok
- Ki végzi
- University Hospital Of Clermont-Ferrand
- Hol
- Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 4. fázis
- Résztvevők
- 55 fő, tervezett
- Kezdés
- 2023. nov. 7.
- Várható befejezés
- 2028. ápr. 14.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. november 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 50 to 70 with osteoarthritis (joint wear) of the hip or knee that causes pain when walking. They will join a walking program and take an anti-inflammatory drug (NSAID) for short periods.
- Életkor
- 50 to 70 years
- Nem
- Men and women
- A betegség stádiuma
- Idiopathic osteoarthritis (joint wear with no known cause) of one or both hips or knees, confirmed by American College of Rheumatology criteria. Joint pain for at least half the time in the last 3 months. Kellgren and Lawrence stage ≥ 2 on an x-ray. Walking pain of at least 4 on a 0 to 10 scale, with limited walking. Fewer than 3 longer walks (at least 20 minutes or 1000 meters) per week.
- Korábbi kezelés
- No steroid injection into the affected joint or visco-supplementation in the 2 months before joining. No steroid injection into a muscle in the month before. No surgery on the affected joint in the previous 6 months, and no arthroscopy in the previous 3 months. No new pain treatment in the month before joining. No regular NSAID use or regular strong opioids.
A részvétel fő kizáró okai
- Pregnant or breastfeeding women
- Joint disease caused by another illness, such as inflammatory rheumatism, gout or infection
- Past allergy to NSAIDs or aspirin, or stomach ulcer or bleeding
- Kidney problems (creatinine clearance < 60 mL/min), severe liver problems, or a liver or kidney transplant
- Heart failure (EF < 40%), uncontrolled high blood pressure, insulin-requiring diabetes, or a bleeding disorder
A regiszter feltételei, szó szerint
Mind a 47 feltétel megnézéseKevesebb
Ki vehet részt
- Patient, man or woman aged 50 to 70, suffering from uni- or bilateral idiopathic osteoarthritis of the hip or knee, whose diagnosis is confirmed by compliance with the radio-clinical criteria of the American College of Rheumatology (Altman et al., 1986): Joint pain felt for at least half the time during the last 3 months prior to inclusion /Morning stiffness lasting less than 30 minutes or joint crackling / Kellgren and Lawrence stage ≥ 2 attested by an available x-ray
- Walking pain rated at least 4 on a scale of 0 (no pain) to 10 (worst imaginable pain), associated with consequent limitation of walking ability (declarative)
- Weekly number of significant trips (walking of at least 20 minutes or 1000 meters) < 3
- Ability to comply with protocol requirements and provide informed consent to participate in research
- Comprehension and fluent writing of the French language
- Coverage by a Social Security scheme
Ki nem vehet részt
- Forecast during the period of the initiation study of a non-pharmacological analgesic treatment different from that proposed by the protocol, such as physiotherapy, behavioral therapy (self-management of pain, hypnosis, sophrology, meditation, mindfulness)
- Interventional surgery on one or more joints concerned, in the 6 months preceding the scheduled inclusion during the study period
- Arthroscopy of one or more joints concerned, within 3 months prior to inclusion or scheduled during the study period
- Other major surgery scheduled during the study period
- Chronic pain (especially neuropathic) concomitant with joint pain, considered severe enough to be an obstacle to walking
- History of haemorrhage or gastrointestinal perforation during previous treatment with NSAIDs
- Alcohol dependence or known drug use (e.g. non-prescription opioids, amphetamines, cannabis, cocaine, phencyclidine, etc.)
- Regular concomitant treatment with NSAIDs (taking an anti-aggregating dose of aspirin is possible and will influence the patient's risk classification)
- Concomitant topical NSAID treatment (can be suspended for the duration of the study)
- Provision during the period of the initiation study of a pharmacological analgesic treatment different from that proposed by the protocol, including systemic corticosteroid
- Causal pathology of the suspected or proven arthropathy, such as: inflammatory rheumatism, septic arthritis, recent osteonecrosis, hemochromatosis, Wilson's disease, gout, acromegaly
- Other general osteo-articular pathology such as Paget's or Reiter's disease
- Hypersensitivity to one of the excipients of a treatment provided for in the protocol, which cannot be replaced by an equivalent formulation
- History of hypersensitivity reactions such as: angioedema, asthma, bronchospasm, nasal polyps, rhinitis, urticaria, or other allergic reactions triggered by taking NSAIDs or acetylsalicylic acid
- Active peptic ulcer, history of peptic ulcer or recurrent bleeding (2 or more distinct episodes of documented bleeding or ulceration)
- Congestive heart failure (EF < 40%)
- Insulin-requiring diabetes
- Known bleeding disorder
- Hypersensitivity to paracetamol
- Hypersensitivity to proton pump inhibitors, if protocol-specified clinical conditions indicate such treatment
- According to the NSAID indicated by the clinical conditions provided for in the protocol: ibuprofen: evolving haemorrhage / diclofenac: ischemic heart disease, peripheral arterial disease and/or history of cerebrovascular accident (including transient ischemic attack)
- Presence of any medical condition deemed incompatible with the study by the investigator
- Severe hepatocellular insufficiency, or liver transplantation, or plasma levels of hepatic transaminases exceeding two and a half times the upper limit of normal according to laboratory standards
- Renal impairment defined by an estimated creatinine clearance < 60 mL/min (MDRD) or renal transplantation, or serum creatinine exceeding one and a half times the upper limit of the normal according to laboratory standards
- Concomitant treatment that cannot be suspended during the trial: any agent known to be nephrotoxic / acetylsalicylic acid at anti-inflammatory doses (≥ 1g/dose and/or ≥ 3g/d), and at analgesic or antipyretic doses (≥ 500mg/dose and/or < 3g/d) / anticoagulant (AVK or AOD) / lithium / methotrexate, pemetrexed / ciclosporin, tacrolimus / tenofovir, disoproxil / glucocorticoid / deferasirox / pentoxifylline / potassium-sparing diuretics, potassium / According to the NSAID indicated by the clinical conditions provided for in the protocol : ketoprofen: cardiac glycosides, nicorandil ; diclofenac: digoxin, cytochrome CYP2C9 inhibitors, phenytoin, quinolones
- Pregnant or breastfeeding woman
- Use of a unicompartmental unloading hinged orthosis (indicated for pain predominant in a femoro-tibial compartment of the knee) initiated during the 2 months preceding inclusion, or scheduled during the study period (continuation of older use is possible)
- Intra-articular injection of glucocorticoid into the affected joint(s), during the 2 months preceding inclusion, or scheduled during the study period
- Visco-supplementation in one or more joints concerned, during the 2 months preceding inclusion, or scheduled during the study period
- Intramuscular injection of glucocorticoid during the month preceding inclusion
- Possible progressive hematological or cancerous pathology (with the exception of a basal cell carcinoma for which total excision was recently performed)
- Immunodepression
- Person under guardianship, curatorship or safeguard of justice, or deprived of freedoms
- Uncontrolled high blood pressure
- Weight < 40 kg or body mass index (BMI) < 19 kg.m–2
- Regular intake of strong or substitute opioids (occasional intake of a strong opioid, or regular intake of tramadol or a weak opioid and paracetamol combination is possible)
- Weight > 130 kg or body mass index (BMI) > 35 kg.m–2
- Participation in another clinical trial, or in a period of exclusion from another clinical trial
- Ambulation not possible
- Use of walking aids other than: cane, crutch, orthosis, knee brace
- Introduction during the month preceding the inclusion of a new analgesic treatment, pharmacological or not
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Study the efficacy and tolerance of the reasoned and punctual intake of a non-steroidal anti-inflammatory drug (NSAID), as part of a walking rehabilitation program for patients suffering from osteoarthritis of the hip or knee.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 2.